KTTA ▼ -3.8% - Pasithea Therapeutics Corp.
$KTTA KTTAW - Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
13-NOV-2026 02:00 AM ET
Share this post
More filings for $KTTA
KTTA - Pasithea Therapeutics Corp. - SEC Filing Update (06-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 6, 2026KTTA - Pasithea Therapeutics Corp. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$KTTA SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026$KTTA SEC Filing Update (01-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 2, 2026$KTTA SEC Filing Update (23-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 23, 2026
View full $KTTA filing history →💬 Comments
Loading comments…
Leave a comment